Evidence map›Paper›PMID 30345421›Full record

ArticleAnnals of research hospitals2018

Further clinical advancement of dendritic cell vaccination against ovarian cancer.

Lauren C Morehead, Martin J Cannon

Abstract read
In one paragraph

Article in Annals of research hospitals, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Artificial Mini Dendritic Cells Boost T Cell-Based Immunotherapy for Ovarian Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lauren C MoreheadDepartment of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Martin J CannonDepartment of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Funding

Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
Zosuquidar trihydrochloride for acute myeloid leukemia &refractory anemiaM01RR000080 · NCRR · UNIVERSITY HOSPITALS OF CLEVELAND · PI DAVIS, PAMELA B · 1985 to 2007
$22.2M
The University of Arkansas for Medical Sciences Initiative for Maximizing Student Development ProgramR25GM083247 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI MCGEHEE, ROBERT E, THOMAS, BILLY R · 2009 to 2023
$5.4M
NCI NIH HHS P50 CA136393NCRR NIH HHS M01 RR000080NIGMS NIH HHS R25 GM083247
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID30345421
PMCPMC6192055

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.